Alpha Tau reports 100% local control in pancreatic cancer trials with Alpha DaRT, showing strong safety and efficacy.

Alpha Tau Medical announced that their Alpha DaRT therapy achieved a 100% local disease control rate in 19 evaluable pancreatic cancer patients across two first-in-human trials. The treatment showed a favorable safety profile with only 8 mild device-related adverse events in 7 of 26 patients, mostly resolving within two weeks. This therapy, delivered via a streamlined endoscopic ultrasound procedure, is designed for patients with limited options, including those ineligible for chemotherapy or heavily pre-treated. These promising results, presented at DDW 2026, suggest Alpha DaRT could become a significant new option for treating pancreatic cancer, with ongoing trials planned to further validate its benefits.